---
figid: PMC9583386__fphar-13-1016836-g003
figtitle: Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease
  and colorectal cancer
organisms:
- Escherichia coli
- Listeria monocytogenes
- Clostridioides difficile
- Clostridioides difficile CD3
- Clostridioides difficile CD8
- Escherichia coli LF82
- Clostridioides difficile CD86
- Clostridioides difficile CD206
- herbal medicine
- Glycyrrhiza uralensis
- Candida metapsilosis
- Dioscorea communis
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- gut metagenome
pmcid: PMC9583386
filename: fphar-13-1016836-g003.jpg
figlink: /pmc/articles/PMC9583386/figure/F3/
number: F3
caption: Targeting FXR to treat CRC. OCA inhibits the occurrence of EMT by activating
  FXR, thus blocking the metastasis of colon cancer cells and promoting the apoptosis
  of cancer cells, increasing the expression of EMT marker gene E-cadherin, and decreasing
  the level of vimentin. The specific mechanism is that OCA promotes the binding of
  FXR to SOCS3 promoter FXRE/IR9, inhibiting the JAK2/STAT3 pathway associated with
  colon cancer.
papertitle: Farnesoid-X receptor as a therapeutic target for inflammatory bowel disease
  and colorectal cancer.
reftext: Mengjiao Zhou, et al. Front Pharmacol. 2022;13:1016836.
year: '2022'
doi: 10.3389/fphar.2022.1016836
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.
keywords: Farnesoid X Receptor | immune cells | post-translational modification |
  inflammatory bowel disease | colorectal cancer | therapy
automl_pathway: 0.9245901
figid_alias: PMC9583386__F3
figtype: Figure
organisms_ner:
- Mus musculus
redirect_from: /figures/PMC9583386__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9583386__fphar-13-1016836-g003.html
  '@type': Dataset
  description: Targeting FXR to treat CRC. OCA inhibits the occurrence of EMT by activating
    FXR, thus blocking the metastasis of colon cancer cells and promoting the apoptosis
    of cancer cells, increasing the expression of EMT marker gene E-cadherin, and
    decreasing the level of vimentin. The specific mechanism is that OCA promotes
    the binding of FXR to SOCS3 promoter FXRE/IR9, inhibiting the JAK2/STAT3 pathway
    associated with colon cancer.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Itk
  - Slc22a3
  - Cdh1
  - Fzr1
  - Nr1h4
  - Ir9
  - Socs3
---
